| abstract |
There is provided a novel series of pyridine or pyrimidine derivatives of Formula I that inhibit CDK9 and may be useful in the treatment of hyperproliferative diseases. In particular, the compounds are useful for the treatment of a proliferative disease, such as a hematologic tumor, such as acute myelogenous leukemia, multiple myeloma, chronic lymphocytic leukemia, broad B cell lymphoma, Burkitt lymphoma, vesicular lymphoma and solid tumors such as breast, lung, neuroblastoma, Lt; RTI ID = 0.0 > cancer. ≪ / RTI > A is C (R < 5 >) or N; R 5 is H, C 1- 3 alkyl, CN or halogen; R 2 is an optionally substituted 3-to 7-membered heterocycloalkyl or 3-to 7-membered cycloalkyl; R 4 is (A) or (B), wherein X and Y, together with the atom to which they are attached, are optionally substituted, which may contain one or two heteroatoms selected from N, O and S, To form a saturated or partially saturated 5 to 7 membered heterocycloalkyl ring; J is N or CR < 11 >; R 11 is H or C 1- 3 alkyl. (I) (A) [Chemical Formula B] |